601 related articles for article (PubMed ID: 24928205)
1. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
2. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
[TBL] [Abstract][Full Text] [Related]
3. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
4. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition.
Wang FZ; Chang ZY; Fei HR; Yang MF; Yang XY; Sun BL
Biochimie; 2014 Aug; 103():118-25. PubMed ID: 24793486
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy enhances DNA damage-induced apoptosis by disrupting CHK1-dependent S phase arrest.
Liou JS; Wu YC; Yen WY; Tang YS; Kakadiya RB; Su TL; Yih LH
Toxicol Appl Pharmacol; 2014 Aug; 278(3):249-58. PubMed ID: 24823293
[TBL] [Abstract][Full Text] [Related]
6. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M
Invest New Drugs; 2016 Oct; 34(5):625-35. PubMed ID: 27350064
[TBL] [Abstract][Full Text] [Related]
10. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
11. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
15. Diallyl disulfide selectively causes checkpoint kinase-1 mediated G2/M arrest in human MGC803 gastric cancer cell line.
Ling H; Lu LF; He J; Xiao GH; Jiang H; Su Q
Oncol Rep; 2014 Nov; 32(5):2274-82. PubMed ID: 25176258
[TBL] [Abstract][Full Text] [Related]
16. Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
Wang Z; Wang M; Kar S; Carr BI
J Cell Physiol; 2009 Oct; 221(1):213-20. PubMed ID: 19530246
[TBL] [Abstract][Full Text] [Related]
17. TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells.
Wu KM; Chi CW; Lai JC; Chen YJ; Kou YR
Cancer Control; 2020; 27(1):1073274819897975. PubMed ID: 32281394
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
19. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.
Chang LC; Yu YL; Liu CY; Cheng YY; Chou RH; Hsieh MT; Lin HY; Hung HY; Huang LJ; Wu YC; Kuo SC
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1303-15. PubMed ID: 25947085
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Hynes SM; Wickremsinhe E; Zhang W; Decker R; Ott J; Chandler J; Mitchell M
Biopharm Drug Dispos; 2015 Jan; 36(1):49-63. PubMed ID: 25296725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]